Therapy. Optimized treatment algorithms for digital vasculopathy in SSc.
Maurizio Cutolo1, Alberto Sulli1
1Research Laboratories and Academic Division of Clinical Rheumatology, Director Postgraduate School on Rheumatology, Department of Internal Medicine, University of Genova, Viale Benedetto XV, 6, 16132 Genova, Italy.
Early detection of secondary Raynaud phenomenon is crucial for managing systemic sclerosis (SSc). New recommendations focus on integrated therapies and monitoring for digital vasculopathy in SSc patients.
Area of Science:
- Rheumatology
- Vascular Medicine
Background:
- Secondary Raynaud phenomenon is a common complication of systemic sclerosis (SSc).
- Prompt diagnosis of secondary Raynaud phenomenon is vital for managing the underlying systemic sclerosis.
Purpose of the Study:
- To present new best practice recommendations for managing digital vasculopathy in SSc.
- To highlight integrated therapeutic approaches and monitoring systems for improved patient care.
Main Methods:
- Review and synthesis of current evidence on digital vasculopathy in SSc.
- Development of updated clinical guidelines based on expert consensus.
Main Results:
- Emphasis on early identification of secondary Raynaud phenomenon.
- Integration of therapeutic strategies and monitoring systems for digital vasculopathy.
Conclusions:
- Adherence to new best practice recommendations can optimize care for SSc patients with digital vasculopathy.
- Improved management of digital vasculopathy may lead to better outcomes in systemic sclerosis.
More Related Videos
10:50Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging
Published on: June 29, 2013
07:18Evaluation of Capillary and Other Vessel Contribution to Macular Perfusion Density Measured with Optical Coherence Tomography Angiography
Published on: February 18, 2022
Related Concept Videos
Peripheral Artery Disease III: Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Atherosclerosis III: Management
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Varicose Veins II: Diagnostic Studies and Interprofessional Care
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
